

# First-in-Human Evaluation of a Hexon Chimeric Adenovirus (IPCAVD 002)

Journal of Infectious Diseases

210, 1052-1061

DOI: [10.1093/infdis/jju217](https://doi.org/10.1093/infdis/jju217)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Infection with Host-Range Mutant Adenovirus 5 Suppresses Innate Immunity and Induces Systemic CD4+ T Cell Activation in Rhesus Macaques. PLoS ONE, 2014, 9, e106004.	2.5	13
3	Engineering Chimeric Adenoviruses. , 2016, , 529-549.		0
4	Methods to Mitigate Immune Responses to Adenoviral Vectors. , 2016, , 391-422.		2
5	Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012). PLoS ONE, 2016, 11, e0166393.	2.5	14
6	New concepts in HIV-1 vaccine development. Current Opinion in Immunology, 2016, 41, 39-46.	5.5	77
7	Adenoviral Vector Vaccines Antigen Transgene. , 2016, , 551-570.		0
8	Adenoviral Vectors Vaccine. , 2016, , 571-590.		1
9	Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5â€‘based Constructs. Molecular Therapy, 2016, 24, 6-16.	8.2	85
10	Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs. Vaccines, 2018, 6, 42.	4.4	8
11	Progress in Adenoviral Capsid-Display Vaccines. Biomedicines, 2018, 6, 81.	3.2	18
12	Designer Oncolytic Adenovirus: Coming of Age. Cancers, 2018, 10, 201.	3.7	69
13	Hexons from adenovirus serotypes 5 and 48 differentially protect adenovirus vectors from neutralization by mouse and human serum. PLoS ONE, 2018, 13, e0192353.	2.5	8
14	Human Immunodeficiency Virus Vaccines. , 2018, , 400-429.e25.		0
15	Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. Nature Communications, 2019, 10, 741.	12.8	46
16	An evidence map of randomised controlled trials evaluating genetic therapies. BMJ Evidence-Based Medicine, 2021, 26, 194-194.	3.5	4
17	Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity. , 2020, 8, e001046.		16
18	Construction and Characterization of a Novel Recombinant Attenuated and Replication-Deficient Candidate Human Adenovirus Type 3 Vaccine: ‘‘Adenovirus Vaccine Within an Adenovirus Vector’’ Virologica Sinica, 2021, 36, 354-364.	3.0	12
19	Capsid Engineering of Adenovirus Vectors: Overcoming Early Vectorâ€‘Host Interactions for Therapy. Human Gene Therapy, 2017, 28, 820-832.	2.7	18

#	ARTICLE	IF	CITATIONS
20	First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients. Oncotarget, 2020, 11, 1273-1288.	1.8	6
21	Development of an Ad5H3 Chimera Using the "Antigen Capsid-Incorporation" Strategy for an Alternative Vaccination Approach. The Open Virology Journal, 2016, 10, 10-20.	1.8	7
24	Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees. Open Forum Infectious Diseases, 2021, 8, ofaa606.	0.9	2
25	The use of adenoviral vectors in gene therapy and vaccine approaches. Genetics and Molecular Biology, 2022, 45, .	1.3	3